Furthermore, in the recent DESTINY-Breast04 study [4], T-DXd resulted in significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with unresectable or metastatic HER2-low breast cancer who had received one or two lines of chemotherapy for metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.